BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation

References

• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13(5):283-96; PMID:22473468
   PubMed Web of Science ®Google Scholar
• Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci 2012; 125(Pt 20):4687-92; PMID:23223894; http://dx.doi.org/10.1242/jcs.093765
   PubMed Web of Science ®Google Scholar
• Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128(1):157-70; PMID:17218262; http://dx.doi.org/10.1016/j.cell.2006.11.042
   PubMed Web of Science ®Google Scholar
• Bassi C, Ho J, Srikumar T, Dowling RJO, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013; 341(6144):395-9; PMID:23888040; http://dx.doi.org/10.1126/science.1236188
   PubMed Web of Science ®Google Scholar
• Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, Pandolfi PP. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011; 144(2):187-99; PMID:21241890; http://dx.doi.org/10.1016/j.cell.2010.12.020
   PubMed Web of Science ®Google Scholar
• Leslie NR, Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 2011; 32(3):131-40.
   Google Scholar
• Correia NC, Gírio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer Oxf Engl 1990 2014; 50(1):216-25
   PubMed Web of Science ®Google Scholar
• Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, Rege-Cambrin G, Cilloni D. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. Ann N Y Acad Sci. 2004; 1028:423-31; PMID:15650267
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7(6):441-53; PMID:17522713; http://dx.doi.org/10.1038/nrc2147
   PubMed Web of Science ®Google Scholar
• Morotti A, Panuzzo C, Fava C, Saglio G. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. Expert Opin Biol Ther 2014; 14(3):287-99; PMID:24387320; http://dx.doi.org/10.1517/14712598.2014.867323
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014; 89(5):547-56; http://dx.doi.org/10.1002/ajh.23691
   PubMed Web of Science ®Google Scholar
• Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, Li S. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010; 115(3):626-35; PMID:19965668; http://dx.doi.org/10.1182/blood-2009-06-228130
   PubMed Web of Science ®Google Scholar
• Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G, Pandolfi PP. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia 2014; 28(6):1326-33; PMID:24317448; http://dx.doi.org/10.1038/leu.2013.370
   PubMed Web of Science ®Google Scholar
• Morotti A, Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G. HAUSP compartmentalization in Chronic Myeloid Leukemia. Eur J Haematol 2014; PMID:25082234
   PubMed Web of Science ®Google Scholar
• Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86(2):726-36; PMID:7606002
   PubMed Web of Science ®Google Scholar
• Calabretta B, Skorski T. BCR/ABL regulation of PI-3 kinase activity. Leuk Lymphoma 1996; 23(5-6):473-6; PMID:9031078; http://dx.doi.org/10.3109/10428199609054856
   PubMed Web of Science ®Google Scholar
• Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008; 118(9):3038-50; PMID:18704194; http://dx.doi.org/10.1172/JCI33337
   PubMed Web of Science ®Google Scholar
• Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005; 65(6):2047-53; http://dx.doi.org/10.1158/0008-5472.CAN-04-3888
   PubMed Web of Science ®Google Scholar
• Keeshan K, Cotter TG, McKenna SL. Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Br J Haematol 2003; 123(1):34-44; PMID:14510940; http://dx.doi.org/10.1046/j.1365-2141.2003.04538.x
   PubMed Web of Science ®Google Scholar
• Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 2007; 67(14):7045-53; PMID:17638918; http://dx.doi.org/10.1158/0008-5472.CAN-06-4312
   PubMed Web of Science ®Google Scholar
• Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 2013; 27(1):118-29; PMID:22858987; http://dx.doi.org/10.1038/leu.2012.222
   PubMed Web of Science ®Google Scholar
• Ding J, Romani J, Zaborski M, MacLeod RAF, Nagel S, Drexler HG, Quentmeier H. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PloS One 2013; 8(12):e83510; PMID:24349524; http://dx.doi.org/10.1371/journal.pone.0083510
   PubMed Web of Science ®Google Scholar
• Kharas MG, Deane JA, Wong S, O’Bosky KR, Rosenberg N, Witte ON, Fruman DA. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 2004; 103(11):4268-75; PMID:14976048; http://dx.doi.org/10.1182/blood-2003-07-2193
   PubMed Web of Science ®Google Scholar
• Huang F-F, Zhang L, Wu D-S, Yuan X-Y, Chen F-P, Zeng H, Yu YH, Zhao XL. PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia. PloS One 2014; 9(3):e88298; PMID:24603487; http://dx.doi.org/10.1371/journal.pone.0088298
   PubMed Web of Science ®Google Scholar
• Pellicano F, Scott MT, Helgason GV, Hopcroft LEM, Allan EK, Aspinall-O’Dea M, Copland M, Pierce A, Huntly BJ, Whetton AD, et al. The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors. Stem Cells Dayt Ohio 2014; 32(9):2324-37; http://dx.doi.org/10.1002/stem.1748
   PubMed Web of Science ®Google Scholar
• Hamzah HG, Pierce A, Stewart WA, Peter Downes C, Gray A, Irvine A, Spooncer E, Whetton AD. Chronic myeloid leukemia CD34+ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) and lack a PtdIns(3,4,5)P3 response to cytokines and chemotactic factors; effects reversed by imatinib. Leukemia 2005; 19(10):1851-3; PMID:16107888; http://dx.doi.org/10.1038/sj.leu.2403919
   PubMed Web of Science ®Google Scholar
• Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G, Morotti A. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. PloS One 2014; 9(10):e110682; PMID:25343485; http://dx.doi.org/10.1371/journal.pone.0110682
   PubMed Web of Science ®Google Scholar
• Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001; 276(2):993-8; PMID:11035045; http://dx.doi.org/10.1074/jbc.M009134200
   PubMed Web of Science ®Google Scholar
• Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG. Direct identification of PTEN phosphorylation sites. FEBS Lett 2002; 528(1-3):145-53; PMID:12297295; http://dx.doi.org/10.1016/S0014-5793(02)03274-X
   PubMed Web of Science ®Google Scholar
• Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 2001; 276(52):48627-30; PMID:11707428; http://dx.doi.org/10.1074/jbc.C100556200
   PubMed Web of Science ®Google Scholar
• Battistutta R. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell Mol Life Sci CMLS 2009; 66(11-12):1868-89; http://dx.doi.org/10.1007/s00018-009-9155-x
   PubMed Web of Science ®Google Scholar
• Mishra S, Reichert A, Cunnick J, Senadheera D, Hemmeryckx B, Heisterkamp N, Groffen J. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003; 22(51):8255-62; PMID:14614449; http://dx.doi.org/10.1038/sj.onc.1207156
   PubMed Web of Science ®Google Scholar
• Mishra S, Pertz V, Zhang B, Kaur P, Shimada H, Groffen J, Kazimierczuk Z, Pinna LA, Heisterkamp N. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007; 21(1):178-80; PMID:17082777; http://dx.doi.org/10.1038/sj.leu.2404460
   PubMed Web of Science ®Google Scholar
• Hériché JK, Chambaz EM. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases. Oncogene 1998; 17(1):13-8; http://dx.doi.org/10.1038/sj.onc.1201900
   PubMed Web of Science ®Google Scholar
• Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci CMLS 2009; 66(11-12):1858-67; http://dx.doi.org/10.1007/s00018-009-9154-y
   PubMed Web of Science ®Google Scholar
• Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. Mol Oncol 2013; 7(6):1103-15; PMID:24012109; http://dx.doi.org/10.1016/j.molonc.2013.08.006
   PubMed Web of Science ®Google Scholar
• Odriozola L, Singh G, Hoang T, Chan AM. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 2007; 282(32):23306-15; PMID:17565999; http://dx.doi.org/10.1074/jbc.M611240200
   PubMed Web of Science ®Google Scholar
• Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia 2013; 27(10):2094-6; PMID:23900138; http://dx.doi.org/10.1038/leu.2013.228
   PubMed Web of Science ®Google Scholar
• Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, et al. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia 2014; 28(3):543-53; PMID:24253024; http://dx.doi.org/10.1038/leu.2013.349
   PubMed Web of Science ®Google Scholar
• Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. Oncotarget 2014; 5(1):258-63; PMID:24473900
   PubMed Web of Science ®Google Scholar
• Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG, Barata JT. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116(15):2724-31; PMID:20660292; http://dx.doi.org/10.1182/blood-2010-04-277947
   PubMed Web of Science ®Google Scholar
• Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118(11):3762-74; PMID:18830414; http://dx.doi.org/10.1172/JCI34616
   PubMed Web of Science ®Google Scholar
• Kim JS, Eom JI, Cheong J-W, Choi AJ, Lee JK, Yang WI, Min YH. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 2007; 13(3):1019-28; http://dx.doi.org/10.1158/1078-0432.CCR-06-1602
   PubMed Web of Science ®Google Scholar
• Sommercorn J, Mulligan JA, Lozeman FJ, Krebs EG. Activation of casein kinase II in response to insulin and to epidermal growth factor. Proc Natl Acad Sci U S A 1987; 84(24):8834-8; PMID:3321056; http://dx.doi.org/10.1073/pnas.84.24.8834
   PubMed Web of Science ®Google Scholar
• Epstein RJ. The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe. Front Oncol 2013; 3:304.; PMID:24377088; http://dx.doi.org/10.3389/fonc.2013.00304
   PubMedGoogle Scholar
• Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453(7198):1072-8; PMID:18469801; http://dx.doi.org/10.1038/nature07016
   PubMed Web of Science ®Google Scholar